tbuckley/cabot-search huggingface dataset:
Physical dependence on zopiclone: case reports
Authors: I. R Jones, G. Sullivan
Journal: BMJ (1998)

<h3>Background:</h3> Mesenchymal stem cells (MSCs) have a potential immunomodulatory role in autoimmune disease; however, the qualitative properties and haematopoietic support capacity of MSCs derived from patients with autoimmune disease is unclear. <h3>Objectives:</h3> To further characterise phenotypically and functionally bone marrow (BM)-derived MSCs from patients with systemic sclerosis (SSc). <h3>Methods:</h3> Key parameters of BM-derived MSC function and phenotype were assessed in 12 patients with SSc and compared with 13 healthy normal controls. The parameters included the ability to: form colony-forming unit fibroblasts (CFU-F), differentiate along the adipogenic and osteogenic lineages, express cell surface antigens defining the MSCs population, support normal haematopoiesis and suppress in vitro lymphocyte proliferation induced by either anti-CD3∊ plus anti-CD28 monoclonal antibodies or the mixed lymphocyte reaction. <h3>Results:</h3> SSc MSCs were shown to have a similar characteristic phenotype, capacities to form CFU-F and to differentiate along adipogenic and osteogenic lineages as those of healthy donor MSCs. The ability of SSc MSCs to support long-term haematopoiesis was also identical to that of controls. Both healthy donor and SSc BM MSCs reduced the proliferation of autologous and allogeneic peripheral blood mononuclear cells in a cell number dependent fashion. <h3>Conclusions:</h3> These results show that BM-derived MSCs from patients with SSc under the described culture conditions exhibit the same phenotypic, proliferative, differentiation potential and immunosuppressive properties as their healthy counterparts and could therefore be considered in an autologous setting. Further studies are needed to ensure the quality and safety of large-scale expansion of patient MSCs prior to their potential use in clinical trials.
C2-07: A phase III clinical trial to evaluate the measurement of tumor proliferation using [18F]Fluoro-3' deoxy-3'-L-fluorothymidine (FLT) positron emission tomography in patients with lung cancer
Authors: Jin-Sook Ryu, Seung Jun Oh, Ki-Chun Im, Euy-Nyong Kim, Seung Il Park, Dong Kwan Kim, Yong Hee Kim, Se Jin Chang, Young Mee Cho, Hyun Seung Lee, Dae Hyuk Moon
Journal: Journal of Thoracic Oncology (2007)
A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens
Authors: Kazuhiko Matsuo, Yayoi Yokota, You Zhai, Ying-Shu Quan, Fumio Kamiyama, Yohei Mukai, Naoki Okada, Shinsaku Nakagawa
Journal: Journal of Controlled Release (2012)
THE MEDIATOR OF CELLULAR IMMUNITY
Authors: F. T. Koster, D. D. McGregor
Journal: The Journal of Experimental Medicine (1971)

A substantial portion of the lymphocyte-like cells in induced peritoneal exudates derive from cells which enter the blood by way of the thoracic duct. The migrant cells have been identified as large and medium lymphocytes, but they may also include short-lived small lymphocytes derived from them. Small lymphocytes which have a potentially long circulating life-span are excluded from exudates, although cells of this type predominate in thoracic duct lymph. The results imply that many (perhaps all) of the small round cells in inflamed tissue are members of a line of rapidly proliferating lymphocytes. Specifically committed lymphocytes with precisely these properties are added to the blood of rats infected with Listeria monocytogenes. The localization of committed lymphocytes in inflammatory foci could be the crucial event which enables the host to focus his cellular defenses at sites of bacterial implantation.
Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor Engagement
Authors: James B. Petro, S.M. Jamshedur Rahman, Dean W. Ballard, Wasif N. Khan
Journal: The Journal of Experimental Medicine (2000)

Mutations in the gene encoding Bruton's tyrosine kinase (btk) cause the B cell deficiency diseases X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid) in mice. In vivo and in vitro studies indicate that the BTK protein is essential for B cell survival, cell cycle progression, and proliferation in response to B cell antigen receptor (BCR) stimulation. BCR stimulation leads to the activation of transcription factor nuclear factor (NF)-κB, which in turn regulates genes controlling B cell growth. We now demonstrate that a null mutation in btk known to cause the xid phenotype prevents BCR-induced activation of NF-κB. This defect can be rescued by reconstitution with wild-type BTK. This mutation also interferes with BCR-directed activation of IκB kinase (IKK), which normally targets the NF-κB inhibitor IκBα for degradation. Taken together, these findings indicate that BTK couples IKK and NF-κB to the BCR. Interference with this coupling mechanism may contribute to the B cell deficiencies observed in XLA and xid.
Large-Scale Brain Network Coupling as a Potential Neural Metric for Nicotine Abstinence Effects on Craving and Cognitive Function
Authors: Edythe D. London, Dara G. Ghahremani
Journal: JAMA Psychiatry (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Research on Doctor/Patient Relationship in a General Hospital Setting
Authors: R. Kertész
Journal: Psychotherapy and Psychosomatics (1970)

Studies on doctor/patient relationship should take into account their mutual influences, and the setting where it takes place. The classical curative schema does not include, generally, the patient's feedback. Moreover, a third inanimate member (instrument, drug) is interposed in great part of the communication, although sometimes it is not technically necessary but serves to avoid anxiety provoking emotional encounters. General and particular factors of the studied relationship in a general hospital are described, and some principles of Berne's Transactional Analysis and the results of their application on the doctor/patient dynamics are presented.
Aerosolized Pentamidine Therapy
Authors: Daniel Havlichek
Journal: Annals of Internal Medicine (1988)

Letters and Corrections15 July 1988Aerosolized Pentamidine TherapyDaniel Havlichek, MDDaniel Havlichek, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-2-167 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:RecurrentPneumocystis cariniipneumonia occurs frequently in patients with the acquired immunodeficiency syndrome (AIDS). Because these patients often have reactions to trimethoprim-sulfamethoxazole or pentamidine or both (1), these patients sometimes need treatment with a medication to which they are sensitive. Two small, independent studies (2, 3) have shown that aerosolized pentamidine may be an effective therapy forP. cariniipneumonia in patients with AIDS. Both aerosol regimens were associated with equivalent or fewer toxicities when compared with systemic therapy. In these studies, no patient had known pentamidine intolerance. We report the safe use of aerosolized pentamidine in...References1. Wharton J, Coleman D, and Wofsy C. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective randomized trial. Ann Intern Med. 1986;105:37-44. LinkGoogle Scholar2. Montgomery A, Debs R, and Luce J. Aerosolized pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet. 1987;2:480-3. CrossrefMedlineGoogle Scholar3. Conte J, Hollander H, and Golden J. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia: a pilot study. Ann Intern Med. 1987;107:495-8. LinkGoogle Scholar4. Greenberger P and Patterson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol. 1987;79:484-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Daniel Havlichek, MDAffiliations: Michigan State University East Lansing, MI 48824 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byChronic Fatigue Syndrome in ChildrenPneumocystis cariniiChronic fatigue syndromeViruses and FatigueAntiprotozoal drugsAerosolized pentamidine in HIVAerosolized Pentamidine and Cutaneous EruptionsTimothy G. Berger, MD, Jordan W. Tappero, MD, Gilford S. Leoung, MD, Mark A. Jacobson, MDThe Post-Infectious Chronic Fatigue SyndromeRASH DUE TO NEBULISED PENTAMIDINEMuscular Pain Mechanisms: Brief Review with Special Consideration of Delayed-Onset Muscle Soreness 15 July 1988Volume 109, Issue 2Page: 167-168KeywordsAIDSPatientsPneumocystis carinii pneumoniaPneumoniaToxicity ePublished: 1 December 2008 Issue Published: 15 July 1988 PDF downloadLoading ...
A new nucleic acid–based agent inhibits cytotoxic T lymphocyte–mediated immune disorders
Authors: Chuang-Wei Wang, Wen-Hung Chung, Yi-Fang Cheng, Nien-Wen Ying, Konan Peck, Yuan-Tsong Chen, Shuen-Iu Hung
Journal: Journal of Allergy and Clinical Immunology (2013)
Landmark article May 19, 1945: The surgical treatment of malformations of the heart in which there is pulmonary stenosis or pulmonary atresia. By Alfred Blalock and Helen B. Taussig
Authors: A. Blalock
Journal: JAMA (1984)

Heretofore there has been no satisfactory treatment for pulmonary stenosis and pulmonary atresia. A "blue" baby with a malformed heart was considered beyond the reach of surgical aid. During the past three months we have operated on 3 children with severe degrees of pulmonary stenosis and each of the patients appears to be greatly benefited. In the second and third cases, in which there was deep persistent cyanosis, the cyanosis has greatly diminished or has disappeared and the general condition of the patients is proportionally improved. The results are sufficiently encouraging to warrant an early report. The operation here reported and the studies leading thereto were undertaken with the conviction that even though the structure of the heart was grossly abnormal, in many instances it might be possible to alter the course of the circulation in such a manner as to lessen the cyanosis and the resultant disability. It is
Psychological Responses to the Experience of Open Heart Surgery: I
Authors: CHASE PATTERSON KIMBALL
Journal: American Journal of Psychiatry (1969)

In an effort to select criteria predictive of patient response to open heart surgery, 54 patients were interviewed preoperatively and followed postoperatively. They were separated into four groups on the basis of previous adjustment, anxiety regarding the operation, and orientation to the future. Postoperatively, the highest mortality occurred in group IV ("Depressed"). Morbidity was greatest in groups II ("Symbiotic") and III ("Anxious"), while most improvement, based on actual functioning in a role capacity, was noted in group I ("Adjusted"). Factors related to the care of these patients at the time of surgery are discussed.
A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients.
Authors: E el-Omar, I Penman, J E Ardill, K E McColl
Journal: Gut (1995)

Acid secretion in response to gastrin releasing peptide (GRP) is increased six-fold in Helicobacter pylori positive duodenal ulcer (DU) patients and threefold in H pylori positive healthy volunteers, and this fully resolves after eradication of the infection. This study was undertaken to determine whether a proportion of H pylori positive patients with non-ulcer dyspepsia (NUD) have an acid secretion disturbance similar to DU patients. Basal and GRP stimulated gastrin concentrations and acid output were examined in 25 H pylori positive NUD patients and the results compared with those of 25 H pylori positive healthy volunteers, 25 H pylori negative healthy volunteers, and 25 H pylori positive DU patients. Compared with the H pylori negative healthy volunteers, GRP stimulated gastrin was increased approximately three fold in each of the three infected groups. GRP stimulated acid secretion (median, range) was higher in the H pylori positive NUD patients (29.6 mmol/h (5.2-46.5)) (p < 0.005) than in the H pylori positive healthy volunteers (19.0 (1.0-38.3)) (p < 0.001) or H pylori negative healthy volunteers (6.3 (2.8-20.9)) (p < 0.0001). The H pylori positive NUD patients, however, had lower acid output than the DU patients (39.1 (17.9-64)) (p < 0.005). These findings are consistent with approximately 50% of the NUD patients having a similar disturbance of GRP stimulated acid secretion to DU patients.
Breaking bad news: why is it still so difficult?
Authors: R Buckman
Journal: BMJ (1984)

Asthma I Avoid precipitating factors if possible 4 Frequency of attacks ?Persistent Infrequent Frequent l-<7 per 2 monthsh-.(>1 per 2 months) Severe Mild Agonist regularly # Agonist as necessary p Agonist as necessary | Agonist as necessary + sodum cromoglycate + + sodium cromoglycate |-}3Agonit regulrly | |Course of oral steroids P6 Agonist regulairly at home + inhaled steroid + Facilities for self referral aeb uher or neuliser Regular g ag Short course of oral steroids for hospital admission Increase dose of 9 agonist Course of oral steroids Regular 8 agonist i F+ Nebuliser at home at home + inhaled steroids Look for additional bronchodilator effect of iprotropium bromide C o l s w i ~~~~~~~~~~~~~~~~~~~~~~~~Course of oral steroids Increase dose.ofinhaled + Teach patient or relatives Increase dose of ihaled to give subcutaneous steroid terbutaline A Add theophylline Add theophylline * Progression down the page indicates inadequate control AlentIdyoa (check blood value) with the treatment above.Alternate day oral * Check inhaler technique regularly.Correct or use another Oral corticosteroids device as necessary.Some of the fears that doctors may have FEAR OF BEING BLAMEDThe worst fear for doctors-particularly junior doctors-is that the patient will blame them personally for the bad news that they bring.Of course, the phenomenon of identifying the bad news with on 2 August
Abstract 2412: Sorafenib can be effectively combined with GM-CSF secreting cellular immunotherapy in a mouse model of HER-2+ breast cancer
Authors: Justin P. Edwards, James M. Leatherman, Steven R. Goding, Melek M. Erdinc, Leisha A. Emens
Journal: Cancer Research (2010)

Abstract Due to the complexities of the tumor microenvironment and the frequent emergence of drug resistance with treatment, it is increasingly evident that cancer therapy will have to hit multiple host and tumor targets simultaneously. We previously reported that DC101, an antiangiogenic monoclonal antibody specific for the vascular endothelial growth factor receptor-2 (VEGFR-2), can enhance tumor immunity by a T cell-dependent mechanism. Sorafenib, a small molecule that also disrupts angiogenesis, blocks signaling through multiple kinases that control tumor growth and progression. It has also been reported to inhibit both dendritic cell (DC) and T cell function. To further explore the intrinsic tumor- and host-based effects of sorafenib, we tested it against murine HER-2+ breast tumor cells (NT) in vitro, and in NT-tumor-bearing FVB/N (immune-competent) and neu-N (immune tolerant to HER-2) mice in vivo. Sorafenib inhibited the growth of NT tumor cells in vitro, inducing apoptosis. Western blot analysis revealed that Sorafenib interfered with ERK/MAPK, but not AKT, signaling pathways, both of which are constitutively activated when HER-2 is over-expressed. Single agent sorafenib effectively controlled the growth of established tumors in immune competent FVB/N mice, but did not result in complete tumor clearance. In contrast, sorafenib alone did not significantly impact the outgrowth of established tumors in neu-N mice, where tumor-specific immune tolerance is in play. Consistent with this observation, depletion studies conducted in immune competent FVB/N mice revealed that the control of tumor growth is in part dependent on T cells, but not macrophages or NK cells. While sorafenib treatment alone did not induce immunity specific for RNEU420–429 (the immunodominant HER-2 epitope), it did accelerate tumor clearance induced by vaccination with a granulocyte-macrophage colony-simulating factor (GM-CSF)-secreting, HER-2+ cellular vaccine in tumor-bearing FVB/N mice compared to either drug treatment or vaccination alone. Finally, sorafenib neither augmented nor inhibited the vaccine-induced T cell response specific for RNEU420–429 as measured by ELISPOT and intracellular cytokine staining. Overall, these findings suggest that vaccine-based immunotherapy can interact with kinase inhibitors by distinct mechanisms for enhanced therapeutic response. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2412.
Diabetes consensus panel calls for action on obesity, diet, and exercise
Authors: C. Wright
Journal: BMJ (2010)

Greater leadership is needed from governments to tackle the epidemic of obesity, promote healthier diets, increase physical activity, and inform transport and planning policies, a consensus panel on diabetes concluded last week.

The panel, which met at the Royal College of Physicians of Edinburgh, said that the government should translate the lessons it had learnt from effective legislation on smoking to the food, drink, and catering sectors.

It also recommended extending the current restrictions on advertising of “less healthy” food and drink that now exist on children’s television across all media.

It came down against a national, population based screening programme for diabetes on the grounds that evidence to support it was insufficient. But it concluded that there was good evidence that lifestyle interventions in high risk groups …
THE EXTENSION OF HOSPITAL PRIVILEGES TO ALL PRACTITIONERS OF MEDICINE
Authors: S. S. GOLDWATER
Journal: JAMA (1925)

Hospitals that are not under the control of medical schools may think that in the matter of medical education theirs is only a subordinate and unimportant part. In fact, their position is not only important: it is supremely important; for, while the medical school may sell the student his admission ticket to the play, seats are not ordinarily reserved, and it remains for the hospital eventually to usher the medical graduate to his place. It was this thought chiefly that prompted me to attempt, at this time, to enlist interest in the extension of hospital privileges to all practitioners of medicine. It seemed especially appropriate that, at a conference on medical education, one who is, in a sense, an official spokesman for hospitals, should urge that the most effective possible use should be made of the extensive facilities for medical education that hospitals control. These thoughts were reinforced by the
Protective and curative effects of topically applied CX-659S, a novel diaminouracil derivative, on chronic picryl chloride-induced contact hypersensitivity responses
Authors: Y. Inoue, M. Isobe, T. Shiohara, Y. Goto, H. Hayashi
Journal: British Journal of Dermatology (2002)

Summary Background CX‐659S, a newly discovered anti‐inflammatory compound, exerts inhibitory effects against acute contact hypersensitivity responses (CHRs) induced by picryl chloride (PC), oxazolone and dinitrochlorobenzene. The murine model of chronic CHR induced by repeated application of PC is known to mimic many, if not all, events occurring within the lesional skin of patients with atopic dermatitis (AD). Objectives To investigate the ability of CX‐659S to inhibit PC‐induced chronic CHR in mice. Methods The protective and curative effects of CX‐659S were tested on PC‐treated ears of BALB/c mice, and were compared with those of prednisolone. Effects were quantified by measurements of ear thickness, serum IgE and cytokine mRNA expression. Results Both protectively applied and curatively applied CX‐659S significantly inhibited increases in ear thickness and total serum IgE. Inhibition was dose‐dependent. Although protectively applied prednisolone showed similar activities to CX‐659S against chronic CHR, curatively applied prednisolone did not affect the serum IgE level despite inhibiting increases in ear thickness and inflammatory cell infiltration. Consistent with these results, CX‐659S reduced mRNA expression of interleukin (IL)‐4 and IL‐10 but not of interferon (IFN)‐γ, whereas prednisolone inhibited not only mRNA expression of IL‐4 and IL‐10 but also that of IFN‐γ in the ear lesion. In contrast to prednisolone, CX‐659S did not show any side‐effect such as atrophy, alopecia or telangiectasia. Conclusions CX‐659S is the first promising compound having inhibitory activities against chronic CHR accompanied by a diminishing effect on elevated serum IgE, without any other side‐effect. Therefore, CX‐659S may be a promising candidate for management of patients with recurring AD who require long‐term therapy.
Every emergency department should have one--an interview room.
Authors: D H Wilson
Journal: BMJ (1976)

The estimated date of a recurrence is not always recorded by a registry, although it gives an indication of the quality of life after treatment as opposed to total survival time.Histology is often not verified, although this varies with region. DATA ANALYSISTechniques used to calculate T-year survival rates vary from the direct method to the life table or actuarial method3 4and the prediction model method5 1i and may or may not be adjusted for the age and sex distribution of the particular group of cancer patients.7This should always be made clear to enable comparisons to be made. DATA PRESENTATIONPresentation of data is largely a matter of common sense, but the publications by Reichmann8 and Mould4 may prove helpful.